Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Pulmonary Sarcoidosis

In brief

This randomized, double-blind, placebo matched to efzofitimod-controlled, study will evaluate the safety, tolerability, immunogenicity, pharmacokinetic (PK), and preliminary efficacy of multiple ascending doses of IV efzofitimod in participants with pulmonary sarcoidosis undergoing a protocol-guided oral corticosteroid (OCS) tapering regimen.This study will consist of 3 staggered multiple dose cohorts. Each eligible participant will participate in only one cohort during the study. Within each cohort, 12 participants will be randomized 2:1 to efzofitimod (N=8) or placebo matched to efzofitimod (N=4).

Key facts

Study ID
NCT03824392
Run by
aTyr Pharma, Inc.
People needed
37
Starts
2019-01-29
Expected to finish
2021-06-29
Last updated by the study team
2023-07-18

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.